Efzofitimod Fails to Cut Steroid Use in Sarcoidosis

A Phase 3 trial found the experimental drug did not significantly reduce oral corticosteroid needs versus placebo in pulmonary sarcoidosis.

Updated on Nov. 19, 2026 in Diseases — General

Bold flat-color vector editorial illustration of two clear vessels joined by a thin tube against a warm off-white field, suggesting a clinical treatment comparison.
Efzofitimod did not significantly reduce oral corticosteroid needs compared with placebo in adults with pulmonary sarcoidosis, a Phase 3 trial found. AI Illustration. Upload story photo >

The Phase 3 EFZO-FIT trial found that efzofitimod did not significantly reduce oral corticosteroid requirements compared with placebo in adults with pulmonary sarcoidosis. The drug was generally well tolerated among the 268 participants.

Why it matters

Corticosteroids are the standard treatment for pulmonary sarcoidosis but carry long-term side effects, so a drug that could limit steroid exposure was an important goal. The negative result means efzofitimod does not currently offer that steroid-sparing benefit for patients.

The trial enrolled 268 adults across 85 centers in nine countries and tracked corticosteroid use over 48 weeks. Placebo-adjusted reductions were 0.02 mg/day at 3 mg/kg and -0.73 mg/day at 5 mg/kg, with confidence intervals spanning zero.

The players

EFZO-FIT trial

A multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating efzofitimod in pulmonary sarcoidosis, published in The Lancet Respiratory Medicine.

Efzofitimod

An investigational immune-regulating therapy that targets the neuropilin-2 receptor and was tested as a way to reduce corticosteroid dependence in sarcoidosis.

The details

Participants received monthly intravenous infusions of efzofitimod at 3 mg/kg or 5 mg/kg, or placebo, over 48 weeks, after all groups completed a structured 12-week oral corticosteroid taper. Efzofitimod targets neuropilin-2, a receptor involved in immune regulation, and was designed to reduce granulomatous inflammation while limiting long-term steroid exposure.

Timeline

  1. 48 weeks: Duration of efzofitimod or placebo treatment in the trial.

  2. 12-week: Structured oral corticosteroid taper applied to all trial groups.

  3. November 19, 2026: Results were published in Pulmonology Today.

Health Landscape

The result places efzofitimod among investigational approaches seeking to spare patients from prolonged corticosteroid therapy, which remains the mainstay of sarcoidosis treatment. Its failure on this primary steroid-reduction endpoint shows how difficult it has been to find a non-steroid alternative that matches corticosteroid efficacy in this disease.

For people with pulmonary sarcoidosis, the trial means efzofitimod should not be expected to cut current corticosteroid doses, so steroid-based treatment plans remain in place. Patients should continue to discuss any changes to their medication with their treating clinicians.

The takeaway

Efzofitimod did not meet its goal of reducing steroid use, so corticosteroids remain the standard of care for pulmonary sarcoidosis. Patients should not expect a steroid-sparing option from this drug.

Further reading

For more on related conditions, explore Diseases — General coverage on Wisevoter.

Source note: This article includes information reported by Derm Immuno Today.